Author:
Donoghoe Martin C.,Bollerup Annemarie R.,Lazarus Jeffrey V.,Nielsen Stine,Matic Srdan
Subject
Health Policy,Medicine (miscellaneous)
Reference37 articles.
1. Antiretroviral treatment for injecting drug users in developing and transitional countries one year before the end of the “Treating 3 million by 2005 Making it happen. The WHO strategy” (3by5);Aceijas;Addiction,2006
2. Provider assessment of adherence to HIV antiretroviral therapy;Bangsberg;Journal of Acquired Immune Deficiency Syndromes,2001
3. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study;Bassetti;Journal of Acquired Immune Deficiency Syndromes,1999
4. Impact of medical and non-medical factors on physician decision making for HIV/AIDS antiretroviral treatment;Bogart;Journal of Acquired Immune Deficiency Syndromes,2000
5. Bollerup, A. R., Lazarus J., Donoghoe, M. C., Nielsen, S., & Matic S. (submitted for publication). Equity of access to highly active antiretroviral therapy (HAART) in the WHO European Region. WHO Bulletin.